WO1996007429A1 - Liquid immunoglobulin formulations - Google Patents
Liquid immunoglobulin formulations Download PDFInfo
- Publication number
- WO1996007429A1 WO1996007429A1 PCT/EP1995/003522 EP9503522W WO9607429A1 WO 1996007429 A1 WO1996007429 A1 WO 1996007429A1 EP 9503522 W EP9503522 W EP 9503522W WO 9607429 A1 WO9607429 A1 WO 9607429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- amphiphilic
- igg
- liquid
- proline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- This invention relates to stable preparations of immunoglobulins.
- immunoglobulin preparations particularly intravenously injectable forms of IgG (iv-IgG) from fractions of human blood plasma.
- IgG intravenously injectable forms of IgG
- it is necessary to remove or to avoid the formation of aggregates which have anticomplementary activity and which, if injected intravenously, can give rise to severe side reactions including anaphylactic shock.
- iv-IgG preparations available for clinical use are lyophilized (freeze-dried) for improved stability on storage, but such preparations must be reconstituted with diluent, e.g. sterile water or saline, before use.
- compositions of iv-IgG which are intended to be stored and used in liquid (aqueous solution) form and which have the necessary degree of stability for such storage.
- Such compositions are referred to hereinafter as liquid preparations of iv- IgG.
- IgG products for intravenous injection contain only very small amounts of aggregates (trimers or higher polymers of IgG molecules), they may contain quite large amounts of IgG dimers, as may be determined for example by high pressure liquid chro atography (HPLC). These dimers do not give rise to anaphylactic shock, and generally have not been regarded as a problem. Indeed in many product specifications, monomers and dimers are considered together under a heading such as "functional IgG". It has been found by Tankersley et al (Molecular Immunology 25, 41-48 1988) that the dimer content of IgG preparations is higher the more donors contribute to the plasma pool from which the IgG was obtained.
- IgG dimers are idiotype-anti-idiotype dimers which are formed when an antibody from one donor recognises the antigen-binding region of an antibody from a different donor and binds to it. Dimers and monomers are present in equilibrium, and the dimer content increases with total immunoglobulin concentration.
- dimer formation increases with storage time; the dimer content of a typical preparation may double during the first week of storage, and continue to rise slowly thereafter.
- an IgG preparation is lyophilized shortly after it is produced, this increase in dimer formation is prevented from taking place.
- the preparation is intended to be stored and used in liquid form, the dimer concentration will increase on storage.
- dimer formation may occur in immunoglobulins other than IgG, for example in IgA, IgD and IgE. Furthermore, dimer formation is also observed in preparations of monoclonal antibodies, although the mechanism of dimer formation in MAbs may differ from that proposed by Tankersley et al.
- IgG dimer unlike higher polymers, does not cause anaphylactic shock, nevertheless IgG preparations with a high dimer content are less well tolerated on intravenous injection and can give rise to undesirable side effects including fever, nausea and sometimes lowered blood pressure. Hypotensive side effects have been detected in a rat model by Bleeker et al (Vox Sanguinis 52, 281-290, 1987), and this also shows an apparent correlation with the dimer content It is therefore desirable to stabilize preparations of immunoglobulins, particularly liquid preparations of iv-IgG, against dimer formation. A number of additives have been used to stabilize iv-IgG and to improve tolerance to it on iv injection.
- glycine examples include glycine; disaccharides, e.g. maltose and saccharose; sugar alcohols, e.g. sorbitol; polyethylene glycol; or small quantities of surfactants such as PEG-20- sorbitanmonooleate or PEG-10-nonyloxyphenol.
- disaccharides e.g. maltose and saccharose
- sugar alcohols e.g. sorbitol
- polyethylene glycol e.g. sorbitol
- surfactants such as PEG-20- sorbitanmonooleate or PEG-10-nonyloxyphenol.
- dimer content is a function of Ig concentration, it is of course possible to reduce dimer content by dilution of the liquid IgG preparations. This approach is not practical, however, as it would require the infusion of unacceptably high volumes of liquid into the patients.
- the problem is solved by the addition to the immunoglobulin formulation of an effective amount of an amphiphilic stabilizer.
- Amphiphilic stabilizers used according to the invention are substances which contain within the molecule a strongly or moderately hydrophilic region as well as a strongly or moderately lipophilic region, but which are not tensides, that is, they do not form micelles in aqueous solution at the concentrations at which they are used, but remain in monomeric form.
- amphiphilic stabilizers of the invention contain within the molecule one or more groups selected from carboxylic acid, sulphonic acid, phosphoric acid, (all in free acid or pharmacologically acceptable salt form), keto-, aldehyde, hydroxy-, amino- or amide groups; as well as one or more lipophilic groups containing from 3 to 12 carbon atoms, preferably from 4 to 10 carbon atoms, and optionally one atom of nitrogen or sulphur. These groups are preferably selected from straight or branched chain alkyl groups, straight or branched chain alkenyl groups, and aromatic, heteroaromatic, aliphatic or heteroaliphatic rings.
- a nitrogen atom is present in the lipophilic group, it is preferably in tertiary form, for example in a pyridine ring.
- Preferred non-cyclic lipophilic groups are branched-chain alkyl groups containing from 4 to 10, preferably 4 to 6 carbon atoms.
- any compound used as stabilizer for iv-IgG must itself be pharmaceutically 4 acceptable for intravenous injection at the concentrations used. It is also preferred that it does not chemically change the IgG molecule, and that it has no significant buffer capacity at pH values between pH 4 and pH 8.
- amphiphilic stabilizers are nicotinic acid and its derivatives, for example nicotinamide, nicotinamide N-oxide and N' -methyl nicotinamide, of which nicotinamide is particularly preferred.
- a further preferred group of amphiphilic stabilizers is that of naturally-occurring ⁇ - amino acids having uncharged lipophilic side-chains, as well as derivatives of such amino acids in which the carboxylic acid group is replaced by a group of formula -CONH 2 , - CONHR, -CH 2 OH, or -COOR, where R is C -alkyl.
- Such amino acids are phenylalanine, methionine, leucine, isoleucine, proline and valine, of which phenylalanine, proline, leucine and isoleucine; particularly proline, leucine and isoleucine; more particularly proline are preferred.
- Japanese Patent Publication No 61-194035 discloses liquid gamma-globulin preparations which are subjected to heat treatment in the presence of a stabilizer which is a monosaccharide, disaccharide or sugar alcohol in the amount of 10 - 100 g / 100 ml and an auxiliary stabilizer which may be a neutral amino acid for example valine, leucine or isoleucine, or a salt of a carboxylic acid.
- a stabilizer which is a monosaccharide, disaccharide or sugar alcohol in the amount of 10 - 100 g / 100 ml
- an auxiliary stabilizer which may be a neutral amino acid for example valine, leucine or isoleucine, or a salt of a carboxylic acid.
- the present invention provides a liquid immunoglobulin preparation, particularly a liquid preparation of immunoglobulin G for intravenous injection, containing one or more amphiphilic stabilizers, as herein defined, in a total amount of at least 0.2 mmol per gram of immunoglobulin and at a total concentration of at least 20 mmol/litre, provided that, if the preparation contains 100 g/1 or more of monosaccharide, disaccharide or sugar alcohol, then at least one amphiphilic stabilizer is other than a neutral amino acid or a salt of a carboxylic acid, and is preferably selected from nicotinic acid and its derivatives.
- Preferred stabilizers are compositions comprising nicotinamide together with one or more of the above amphiphilic amino acids or their derivatives. More preferred stabilizer compositions comprise nicotinamide and proline, optionally together with one or more additional amphiphilic amino acids. Especially preferred compositions are mixtures of (a) nicotinamide and proline; (b) nicotinamide, proline and isoleucine; and (c) nicotinamide, proline, isoleucine and leucine. Preferably in such compositions the mole ratio of nicotinamide to total amphiphilic amino acids lies between 1:1 and 1:4. The most preferred composition is a mixture of nicotinamide, proline and isoleucine, preferably in a mole ratio of 1 : (0.8 - 2.0) : (0.8 - 2.0).
- the immunoglobulin stabilized according to the invention may be any preparation of IgA, IgD, IgE or IgG, whether polyclonal or monoclonal, and whether isolated from human or animal blood plasma or produced by other means, for example by hybridoma or recombinant DNA technology.
- it is a preparation of IgG from human blood plasma which has been treated so as to be intravenously injectable and which is intended to be stored and used in liquid form.
- it is a polyvalent, intact immunoglobulin which has not been cleaved (for example with high pepsin concentrations) and which retains the structural and functional integrity of the 7S-IgG antibodies, including an intact Fc region.
- it is one obtained from blood serum fractions by a modified alcohol cryoprecipitation including treatment with low concentrations of pepsin at pH 4.
- the IgG content of the liquid formulation is preferably between 3% and 16%, more preferably between 6% and 12%.
- the pH of the solution is preferably from pH 4 to pH 8, more preferably from pH 5 to pH 6, particularly from pH 5.2 to pH 5.4. At such relatively acidic pH values, it is important that the solution have low buffer capacity, to prevent any significant lowering of the pH of the recipient's blood upon intravenous injection.
- the tonicity of the solution may be adjusted to physiological values by the addition of one or more non- buffering substances for example sodium chloride, glycine, sucrose, maltose and sorbitol.
- Such liquid formulations may be administered by intravenous infusion for example at a dosage of 0.2 - 1.0 g of IgG per kg of body weight per day.
- the quantity of amphiphilic stabilizer present in the compositions according to the invention is preferably from 0.2 to 6 mmol per gram of IgG, more preferably 1 to 3 mmol/g IgG.
- the immunoglobulin preparations may also contain other proteins, for example albumin. 6
- a liquid iv-IgG preparation according to the invention containing an amphiphilic stabilizer may be stored for up to 2 years at temperatures between 2 * C and 25 'C without the dimer content rising to unacceptable levels. Such formulations are; well tolerated upon intravenous injection.
- Solutions of iv-IgG which are intended to be lyophilized and sold in solid lyophilized form may also be stabilized by adding amphiphilic stabilizers according to the invention, so as to reduce dimer formation during the time between preparation and lyophilization.
- Crude IgG paste obtained by alcohol fractionation of pooled human blood plasma is dissolved in sterile water at 4°C and filtered.
- the solution is acidified to pH 4 and incubated with a small quantity of pepsin at pH 4, 37"C, then neutralized.
- the product is then diafiltered to remove any remaining alcohol, then the pH is adjusted to pH 5.3 and the solution is concentrated by ultrafiltration to give a final protein concentration of between 6% and 15% w/v.
- the product may also be prepared as described in Swiss Patent No. 684 164.
- AA, AD and AM are the areas of the aggregate, dimer and monomer peaks respectively.
- Liquid iv-IgG preparations are stored at ambient temperature (20-25°C) in sealed containers for periods of 80-90 days, and the dimer content measured at the end of this period.
- Example 1 and for additional Examples 2 - 16 according to the invention together with comparative examples A - G containing no additives or containing glycine only, are shown in Tables 1 and 2 below.
- Table 3 below shows the results of testing four liquid preparations each containing 12% protein in the rat hypotensive model as described by Bleeker et al (Vox Sanguinis 52, 281-290, 1987) after room temperature storage. Preparations according to the invention (Examples 17 - 19) gave only a 5% - 18% drop in blood pressure whereas the unstabilized preparation gave a drop of nearly 50%.
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT95932006T ATE246005T1 (en) | 1994-09-08 | 1995-09-07 | LIQUID IMMUNOGLOBIN FORMULATIONS |
NZ292919A NZ292919A (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations containing one or more non-tenside amphiphilic stabilisers |
DE69531400T DE69531400T2 (en) | 1994-09-08 | 1995-09-07 | LIQUID IMMUNOGLOBIN FORMULATIONS |
PL95318265A PL182738B1 (en) | 1994-09-08 | 1995-09-07 | Liquid composition of immunoglobulins |
JP8509221A JP3004729B2 (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin preparation |
RO97-00420A RO118568B1 (en) | 1994-09-08 | 1995-09-07 | Stable immunoglobulin liquid preparations and process for obtaining the same |
HU9701681A HU223668B1 (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations and method for their preparation |
CZ97684A CZ285967B6 (en) | 1994-09-08 | 1995-09-07 | Stabilized liquid immunoglobulin preparation |
DK95932006T DK0779818T3 (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations |
EP95932006A EP0779818B1 (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations |
AU35229/95A AU700788B2 (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations |
BR9508821A BR9508821A (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations |
SK300-97A SK282332B6 (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations and process for stabilisation of these formulations |
CA002197432A CA2197432C (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations |
MX9701510A MX9701510A (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations. |
FI970603A FI970603A (en) | 1994-09-08 | 1997-02-12 | Immunoglobulin liquid formulations |
NO971016A NO971016D0 (en) | 1994-09-08 | 1997-03-05 | Liquid immunoglobulin preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9418092A GB9418092D0 (en) | 1994-09-08 | 1994-09-08 | Organic compounds |
GB9418092.4 | 1994-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996007429A1 true WO1996007429A1 (en) | 1996-03-14 |
Family
ID=10761028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/003522 WO1996007429A1 (en) | 1994-09-08 | 1995-09-07 | Liquid immunoglobulin formulations |
Country Status (27)
Country | Link |
---|---|
US (1) | US5871736A (en) |
EP (1) | EP0779818B1 (en) |
JP (1) | JP3004729B2 (en) |
KR (1) | KR100370631B1 (en) |
CN (1) | CN1157572A (en) |
AT (1) | ATE246005T1 (en) |
AU (1) | AU700788B2 (en) |
BR (1) | BR9508821A (en) |
CA (1) | CA2197432C (en) |
CZ (1) | CZ285967B6 (en) |
DE (1) | DE69531400T2 (en) |
DK (1) | DK0779818T3 (en) |
FI (1) | FI970603A (en) |
GB (1) | GB9418092D0 (en) |
HU (1) | HU223668B1 (en) |
IL (1) | IL115226A (en) |
MX (1) | MX9701510A (en) |
NO (1) | NO971016D0 (en) |
NZ (1) | NZ292919A (en) |
PL (1) | PL182738B1 (en) |
PT (1) | PT779818E (en) |
RO (1) | RO118568B1 (en) |
RU (1) | RU2158605C2 (en) |
SK (1) | SK282332B6 (en) |
TW (1) | TW407056B (en) |
WO (1) | WO1996007429A1 (en) |
ZA (1) | ZA957583B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6139838A (en) * | 1996-09-06 | 2000-10-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Tissue plasminogen activator medicinal composition |
US6485932B1 (en) * | 1997-03-20 | 2002-11-26 | Common Services Agency | Composition comprising immunoglobulin |
WO2008079290A2 (en) * | 2006-12-21 | 2008-07-03 | Amgen Inc | Stable buffered formulations containing polypeptides |
WO2011157950A1 (en) | 2010-06-15 | 2011-12-22 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Stabilised human immunoglobulin composition |
US8496930B2 (en) | 2003-10-01 | 2013-07-30 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
US8846046B2 (en) | 2002-10-24 | 2014-09-30 | Abbvie Biotechnology Ltd. | Low dose methods for treating disorders in which TNFα activity is detrimental |
US8895266B2 (en) | 2000-10-06 | 2014-11-25 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US8906368B2 (en) | 2003-11-18 | 2014-12-09 | Zlb Behring Ag | Immunoglobulin preparations having increased stability |
US8911741B2 (en) | 2002-08-16 | 2014-12-16 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
EP2873422A4 (en) * | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | Pharmaceutical preparation for injection |
US9241897B2 (en) | 2010-02-04 | 2016-01-26 | Csl Behring Ag | Immunoglobulin preparation |
AU2014201388B2 (en) * | 2006-12-21 | 2016-05-12 | Amgen Inc. | Stable Buffered Formulations Containing Polypeptides |
US9422364B2 (en) | 2010-02-26 | 2016-08-23 | Csl Behring Ag | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
US10233247B2 (en) | 1999-04-09 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Method of modulating the activity of functional immune molecules |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
EP1324776B2 (en) * | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US20040208869A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Uses of anti-integrin alphanubeta3 antibody formulations |
ES2349779T5 (en) | 2003-04-04 | 2013-11-26 | Genentech, Inc. | Antibody and protein formulations at high concentration |
DE10333317A1 (en) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulation for protein medicines without the addition of human serum albumin (HSA) |
JP5513380B2 (en) * | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | Composition of specific binding agents for hepatocyte growth factor |
KR101087017B1 (en) * | 2007-07-10 | 2011-12-09 | (주)메디톡스 | Stable liquid composition of Botulinum Toxin |
US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
TWI489994B (en) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
CA2754528A1 (en) * | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
EP3708581A3 (en) | 2009-05-27 | 2021-10-20 | Takeda Pharmaceutical Company Limited | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
PT2616090T (en) | 2010-09-17 | 2023-10-16 | Takeda Pharmaceuticals Co | Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
KR102435648B1 (en) | 2013-09-11 | 2022-08-25 | 이글 바이오로직스 인코퍼레이티드 | Liquid protein formulations containing viscosity-lowering agents |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US11471479B2 (en) | 2014-10-01 | 2022-10-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
US20240052020A1 (en) * | 2020-09-27 | 2024-02-15 | Emergent Biosolutions Canada Inc. | Hyperimmune globulin formulations |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0025275A2 (en) * | 1979-08-09 | 1981-03-18 | Teijin Limited | Immunoglobulin-containing composition containing an aggregation preventing or aggregate dissociating agent for the immunoglobulin, and process for preparation thereof |
EP0037078A2 (en) * | 1980-03-27 | 1981-10-07 | Green Cross Corporation | Process for heat treatment of aqueous solution containing human blood coagulation factor XIII |
JPS60120823A (en) * | 1983-12-02 | 1985-06-28 | Green Cross Corp:The | Igg monomer |
EP0187712A2 (en) * | 1985-01-09 | 1986-07-16 | Ortho Diagnostic Systems Inc. | Stabilized immunoglobulin and method of preparation |
JPS61194035A (en) * | 1985-05-16 | 1986-08-28 | Green Cross Corp:The | Gamma-globulin preparation |
EP0196761A2 (en) * | 1985-02-21 | 1986-10-08 | Green Cross Corporation | Method of virus-inactivating heat treatment of gamma-globulin |
EP0392717A1 (en) * | 1989-04-04 | 1990-10-17 | Eli Lilly And Company | Pharmaceutical formulations containing immunoglobulin conjugates |
JPH05178719A (en) * | 1991-12-26 | 1993-07-20 | Kanebo Ltd | Stabilization of antibody, aqueous composition and cosmetic |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4360457A (en) * | 1979-08-30 | 1982-11-23 | Teijin Limited | S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof |
-
1994
- 1994-09-08 GB GB9418092A patent/GB9418092D0/en active Pending
-
1995
- 1995-09-07 MX MX9701510A patent/MX9701510A/en not_active IP Right Cessation
- 1995-09-07 CN CN95194957A patent/CN1157572A/en active Pending
- 1995-09-07 BR BR9508821A patent/BR9508821A/en not_active Application Discontinuation
- 1995-09-07 JP JP8509221A patent/JP3004729B2/en not_active Expired - Fee Related
- 1995-09-07 NZ NZ292919A patent/NZ292919A/en not_active IP Right Cessation
- 1995-09-07 CZ CZ97684A patent/CZ285967B6/en not_active IP Right Cessation
- 1995-09-07 HU HU9701681A patent/HU223668B1/en not_active IP Right Cessation
- 1995-09-07 EP EP95932006A patent/EP0779818B1/en not_active Expired - Lifetime
- 1995-09-07 AT AT95932006T patent/ATE246005T1/en not_active IP Right Cessation
- 1995-09-07 RU RU97105363/14A patent/RU2158605C2/en not_active IP Right Cessation
- 1995-09-07 RO RO97-00420A patent/RO118568B1/en unknown
- 1995-09-07 AU AU35229/95A patent/AU700788B2/en not_active Ceased
- 1995-09-07 CA CA002197432A patent/CA2197432C/en not_active Expired - Fee Related
- 1995-09-07 DE DE69531400T patent/DE69531400T2/en not_active Expired - Lifetime
- 1995-09-07 DK DK95932006T patent/DK0779818T3/en active
- 1995-09-07 PT PT95932006T patent/PT779818E/en unknown
- 1995-09-07 SK SK300-97A patent/SK282332B6/en not_active IP Right Cessation
- 1995-09-07 WO PCT/EP1995/003522 patent/WO1996007429A1/en active IP Right Grant
- 1995-09-07 PL PL95318265A patent/PL182738B1/en not_active IP Right Cessation
- 1995-09-07 KR KR1019970701102A patent/KR100370631B1/en not_active IP Right Cessation
- 1995-09-08 ZA ZA957583A patent/ZA957583B/en unknown
- 1995-09-08 IL IL11522695A patent/IL115226A/en not_active IP Right Cessation
- 1995-09-11 TW TW084109552A patent/TW407056B/en not_active IP Right Cessation
-
1997
- 1997-02-12 FI FI970603A patent/FI970603A/en not_active IP Right Cessation
- 1997-03-05 NO NO971016A patent/NO971016D0/en not_active Application Discontinuation
- 1997-03-07 US US08/813,219 patent/US5871736A/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0025275A2 (en) * | 1979-08-09 | 1981-03-18 | Teijin Limited | Immunoglobulin-containing composition containing an aggregation preventing or aggregate dissociating agent for the immunoglobulin, and process for preparation thereof |
EP0037078A2 (en) * | 1980-03-27 | 1981-10-07 | Green Cross Corporation | Process for heat treatment of aqueous solution containing human blood coagulation factor XIII |
JPS60120823A (en) * | 1983-12-02 | 1985-06-28 | Green Cross Corp:The | Igg monomer |
EP0187712A2 (en) * | 1985-01-09 | 1986-07-16 | Ortho Diagnostic Systems Inc. | Stabilized immunoglobulin and method of preparation |
EP0196761A2 (en) * | 1985-02-21 | 1986-10-08 | Green Cross Corporation | Method of virus-inactivating heat treatment of gamma-globulin |
JPS61194035A (en) * | 1985-05-16 | 1986-08-28 | Green Cross Corp:The | Gamma-globulin preparation |
EP0392717A1 (en) * | 1989-04-04 | 1990-10-17 | Eli Lilly And Company | Pharmaceutical formulations containing immunoglobulin conjugates |
JPH05178719A (en) * | 1991-12-26 | 1993-07-20 | Kanebo Ltd | Stabilization of antibody, aqueous composition and cosmetic |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 8532, Derwent World Patents Index; Class B04, AN 85-193554 * |
DATABASE WPI Section Ch Week 9333, Derwent World Patents Index; Class B04, AN 93-261569 * |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6139838A (en) * | 1996-09-06 | 2000-10-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Tissue plasminogen activator medicinal composition |
US6485932B1 (en) * | 1997-03-20 | 2002-11-26 | Common Services Agency | Composition comprising immunoglobulin |
US10233247B2 (en) | 1999-04-09 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Method of modulating the activity of functional immune molecules |
US8895266B2 (en) | 2000-10-06 | 2014-11-25 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US9409982B2 (en) | 2000-10-06 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US10233475B2 (en) | 2000-10-06 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US9738714B2 (en) | 2002-08-16 | 2017-08-22 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9114166B2 (en) | 2002-08-16 | 2015-08-25 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US9327032B2 (en) | 2002-08-16 | 2016-05-03 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9302011B2 (en) | 2002-08-16 | 2016-04-05 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-α associated disorders |
US8911741B2 (en) | 2002-08-16 | 2014-12-16 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
US8916157B2 (en) | 2002-08-16 | 2014-12-23 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8916158B2 (en) | 2002-08-16 | 2014-12-23 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8932591B2 (en) | 2002-08-16 | 2015-01-13 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8940305B2 (en) | 2002-08-16 | 2015-01-27 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US9295725B2 (en) | 2002-08-16 | 2016-03-29 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9732152B2 (en) | 2002-08-16 | 2017-08-15 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9289497B2 (en) | 2002-08-16 | 2016-03-22 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9272041B2 (en) | 2002-08-16 | 2016-03-01 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9220781B2 (en) | 2002-08-16 | 2015-12-29 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9750808B2 (en) | 2002-08-16 | 2017-09-05 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9950066B2 (en) | 2002-08-16 | 2018-04-24 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9272042B2 (en) | 2002-08-16 | 2016-03-01 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US8846046B2 (en) | 2002-10-24 | 2014-09-30 | Abbvie Biotechnology Ltd. | Low dose methods for treating disorders in which TNFα activity is detrimental |
US8496930B2 (en) | 2003-10-01 | 2013-07-30 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
US9011850B2 (en) | 2003-10-01 | 2015-04-21 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
US10172790B2 (en) | 2003-10-01 | 2019-01-08 | Kyowa Hakko Kirin Co., Ltd | Method of stabilizing antibody and stabilized solution-type antibody preparation |
US8906368B2 (en) | 2003-11-18 | 2014-12-09 | Zlb Behring Ag | Immunoglobulin preparations having increased stability |
EP1687028B2 (en) † | 2003-11-18 | 2015-11-04 | CSL Behring AG | Immunoglobulin preparations having increased stability |
AU2014201388B2 (en) * | 2006-12-21 | 2016-05-12 | Amgen Inc. | Stable Buffered Formulations Containing Polypeptides |
AU2014201388C1 (en) * | 2006-12-21 | 2017-02-02 | Amgen Inc. | Stable Buffered Formulations Containing Polypeptides |
AU2007338791B2 (en) * | 2006-12-21 | 2014-03-13 | Amgen Inc | Stable buffered formulations containing polypeptides |
WO2008079290A3 (en) * | 2006-12-21 | 2008-12-04 | Amgen Inc | Stable buffered formulations containing polypeptides |
WO2008079290A2 (en) * | 2006-12-21 | 2008-07-03 | Amgen Inc | Stable buffered formulations containing polypeptides |
US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
US9241897B2 (en) | 2010-02-04 | 2016-01-26 | Csl Behring Ag | Immunoglobulin preparation |
US10137197B2 (en) | 2010-02-04 | 2018-11-27 | Csl Behring Ag | Process for preparing an immunoglobulin preparation |
US9422364B2 (en) | 2010-02-26 | 2016-08-23 | Csl Behring Ag | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
US10434176B2 (en) | 2010-02-26 | 2019-10-08 | Csl Behring Ag | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
US11419936B2 (en) | 2010-02-26 | 2022-08-23 | Csl Behring Ag | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
WO2011157950A1 (en) | 2010-06-15 | 2011-12-22 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Stabilised human immunoglobulin composition |
EP2873422A4 (en) * | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | Pharmaceutical preparation for injection |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2197432C (en) | Liquid immunoglobulin formulations | |
AU2004290899B2 (en) | Immunoglobulin preparations having increased stability | |
KR101673654B1 (en) | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc | |
CA2851646A1 (en) | Etanercept formulations stabilized with meglumine | |
IL272513B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
EA043419B1 (en) | METHOD FOR OBTAINING LYOPHILIZED PHARMACEUTICAL COMPOSITION BASED ON THERAPEUTIC PROTEIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194957.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 292919 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995932006 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2197432 Country of ref document: CA Ref document number: 970603 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970701102 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/001510 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-684 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 30097 Country of ref document: SK Ref document number: 97-00420 Country of ref document: RO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08813219 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-684 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 1997 809308 Country of ref document: US Date of ref document: 19970617 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1995932006 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970701102 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-684 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970701102 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995932006 Country of ref document: EP |